LFG
CLSD

Larson Financial Group’s Clearside Biomedical CLSD Stock Holding History

Larson Financial Group’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-67
Closed -$918 – 3323
2025
Q1 		$918 Buy
+67
New +$962 ﹤0.01% 2411

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Larson Financial Group's CLSD Position: Q2 2025 in Review

Larson Financial Group sold out of Clearside Biomedical (CLSD) in Q2 2025, closing a stake of 67 shares — an estimated $918 sold.

Larson Financial Group first reported a position in CLSD in Q1 2025 and held it in 1 quarter. The position peaked at $918 in Q1 2025. 44 funds tracked by Wall St. Rank hold CLSD as of Q2 2025.

  • Larson Financial Group reported no remaining Clearside Biomedical position as of Q2 2025 after selling out during the quarter.
  • Larson Financial Group sold 67 Clearside Biomedical shares in Q2 2025, an estimated $918.
  • Larson Financial Group first reported a position in Clearside Biomedical in Q1 2025 and held it in 1 quarter.
  • Larson Financial Group's Clearside Biomedical position peaked at $918 in Q1 2025.
  • 44 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2025.

Based on Larson Financial Group's 13F filing for Q2 2025, filed 8 Aug 2025.